HUMA News and Press, Humacyte Inc. From 03/24/23

2023-03-24 11:55:56 ET Humacyte ( NASDAQ: HUMA ) stock fell ~8% on Friday after the company's Q4 results. The company's net loss per share was -$0.04, compared to net income per share of $0.41 in Q4 2021. Humacyte did not have Grant revenue in Q4 compared to $177K ...

2023-03-24 07:04:43 ET Humacyte press release ( NASDAQ: HUMA ): Q4 GAAP EPS of -$0.04 beats by $0.19 . The company reported cash, cash equivalents and short-term investments of $151.9 million as of December 31, 2022, compared to $225.5 million as of December ...

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients -- Multiple publications and scientific meeting presentations highlighting clinical and preclinic...

DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, ...

Summary Humacyte, Inc. develops universally implantable regenerative human tissue for trauma and other uses. The company has solid science, and data is being generated slowly. They have two upcoming BLAs, DoD interest, decent cash, good science, and are priced near 52-week lows. ...

- HAVs observed to provide long-term perfusion to patients with critical limb ischemia - 3D Angiograms show mechanical durability of engineered human blood vessels DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platfor...

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com/events . ...

DURHAM, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary...

The following slide deck was published by Humacyte, Inc. in conjunction with this event. For further details see: Humacyte (HUMA) nvestor Presentation - Slideshow

DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced presentations on the ...